Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The retatrutide availability timeline depends on ongoing clinical trials and regulatory review: Current status: Multiple phase 3 trials (TRIUMPH program) ongoing Phase 3 primary completion: Expected through mid-year NDA submission: Eli Lilly expected to submit to FDA in late future FDA review period: Approximately 10 months after submission Estimated approval: Potentially late next year at earliest Commercial launch: Could follow shortly after approval It is important to note that Eli Lilly has not announced an official filing timeline
Amongst the long list of compounds investigated, a limited number of GSH-conjugates have recently progressed towards clinical trials for the treatment of cancer patients
F , female
Scheme 30
US$ 22.65
US$ 24.15
US$ 28.62
US$ 27.04
US$ 20.01
US$ 29.72
US$ 24.01
US$ 26.90
US$ 29.87
